These findings suggest that IR808-ATIPA enhances radiotherapy efficacy by overcoming tumor resistance through a dual mechanism: It up-regulates BCL2 to counteract the anti-apoptotic effects mediated by Bcl-xL, while down-regulation of MT1E reduces the radical-scavenging capacity of metallothioneins, thereby amplifying oxidative damage in tumor cells. The gene discussed is BCL2; the disease is neoplasm.